ClinicalTrials.gg
TerminatedNCT04855747RELIANCE-IIUpdated Jul 10, 2026Results posted

A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)

A Phase 3 interventional study of REL-1017 and Placebo in Major Depressive Disorder and Depression, sponsored by Levomecor Inc.. Terminated at 70 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Levomecor Inc. · Phase 3, Interventional, and Treatment

Why this study was terminated
Study REL-1017-302 was terminated early by the Sponsor following the prespecified interim analysis for sample size re-estimation at approximately 75% enrollment of the planned sample size (N=280). Safety data were collected.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
236
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,500 studies in Depressive Disorder, Major with a site in United States — 215 open to participants now, 259 under way, 27 of them phase 3. Depressive Disorder, Major · United States.

Enrollment
308th of 1,323
236 · median 70
Started
2021
with 71 others
Phase 3
240 of 1,500
21 open now
Registered
1,121st of 1,500
by date

Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 308th largest by enrollment of the 1,323 interventional ones that give a count, is one of 72 that started in 2021, is one of 240 in phase 3, and was the 1,121st registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

215 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:

210 more — sign in →

All 215 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,500 studies in Depressive Disorder, Major with a site in United States, or all of them as a file.
02

Study summary

This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as an adjunctive treatment of Major Depressive Disorder. Study participants will continue to take their current antidepressant therapy in addition to the study drug or placebo for the duration of the treatment period.

03

Conditions studied

  • Major Depressive Disorder
  • Depression

Keywords

  • REL-1017
  • Relmada
  • NMDA Receptor Antagonist
  • Esmethadone
  • Adjunctive
  • Antidepressant
  • Reliance
  • Depression
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) between 18.0 and 35.0 kg/m2.
  • Diagnosed with Major Depressive Disorder (MDD) based on Structured Clinical Interview for (SCID-5) for MDD.
  • Current Major Depressive Episode (MDE).
  • Treated on approved, stable anti-depressant therapy with inadequate response to 1 to 3 valid courses of treatment with a depressant medication in the current MDE.

Exclusion criteria

Exclusion Criteria:

  • Any current and primary psychiatric disorder other than Major Depressive Disorder.
  • Severe alcohol or substance use disorder.
  • History of bipolar I and II disorder, psychosis, and/or mania.
  • Poorly controlled diabetes as defined by > 7.5%, despite standard care. Subjects with HbA1c >7.5% may continue in the study if approved by the Relmada Medical Monitor.
  • Having received ketamine or esketamine within 60 days prior to Screening.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
236 participants (actual)

Study arms

  • Experimental
    REL-1017 25 mg

    During the double blind treatment period (28 days), participants will take 1 tablet of REL-1017 25 mg, orally, per day in addition to their ongoing antidepressant (ADT)

    Drug: REL-1017

  • Placebo comparator
    Placebo

    During the double blind treatment period (28 days), participants will take 1 tablet of placebo, orally, per day in addition to their ongoing antidepressant (ADT).

    Drug: Placebo

Interventions

  • REL-1017 tablet

    Also known as: Esmethadone

  • DrugPlacebo

    Placebo tablet

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Day 28 in MADRS Total Score

    Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score. The MADRS is a clinician-rated scale that assesses the severity of depressive symptoms. The total score is calculated as the sum of 10 items, each scored from 0 to 6, resulting in a total score range of 0 to 60. Lower scores indicate less severe depressive symptoms and a better outcome, whereas higher scores indicate more severe depressive symptoms and a worse outcome. The outcome measure reports the change in MADRS total score from Baseline to Day 28. Change was calculated as Day 28 score minus Baseline score.

    Time frame: Baseline and Day 28

Secondary outcomes

  1. Change From Baseline to Day 7 in MADRS Total Score

    Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score. The MADRS is a clinician-rated scale that assesses the severity of depressive symptoms. The total score is calculated as the sum of 10 items, each scored from 0 to 6, resulting in a total score range of 0 to 60. Lower scores indicate less severe depressive symptoms and a better outcome, whereas higher scores indicate more severe depressive symptoms and a worse outcome. The outcome measure reports the change in MADRS total score from Baseline to Day 7. Change was calculated as Day 7 score minus Baseline score.

    Time frame: Day 7

  2. Change From Baseline to Day 28 in Clinical Global Impression-Severity (CGI-S) Score

    Clinical Global Impression-Severity (CGI-S) is a clinician-rated assessment of illness severity. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). Lower scores indicate less severe illness and a better outcome, whereas higher scores indicate more severe illness and a worse outcome. The outcome measure reports the change in CGI-S score from Baseline to Day 28. Change was calculated as Day 28 score minus Baseline score

    Time frame: Day 28

  3. MADRS10 Remission Rate at Day 28

    Remission was defined as a Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score ≤10 at Day 28. The MADRS total score ranges from 0 to 60, with lower scores indicating less severe depressive symptoms and a better outcome.

    Time frame: Day 28

  4. MADRS10 Response Rate at Day 28

    Response was defined as a ≥50% reduction from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score. The MADRS total score ranges from 0 to 60, with lower scores indicating less severe depressive symptoms and a better outcome.

    Time frame: Day 28

07

Results

Posted Jul 10, 2026
Limitations and caveats
Study REL-1017-302 was terminated early by the Sponsor following the prespecified interim analysis for sample size re-estimation at approximately 75% enrollment of the planned sample size (N=280). Safety data were collected.

Participant flow

Participant flow — Overall Study
MilestoneREL-1017Placebo
Started119117
Completed110109
Not completed98

Outcome measures

PrimaryChange From Baseline to Day 28 in MADRS Total Score

Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score. The MADRS is a clinician-rated scale that assesses the severity of depressive symptoms. The total score is calculated as the sum of 10 items, each scored from 0 to 6, resulting in a total score range of 0 to 60. Lower scores indicate less severe depressive symptoms and a better outcome, whereas higher scores indicate more severe depressive symptoms and a worse outcome. The outcome measure reports the change in MADRS total score from Baseline to Day 28. Change was calculated as Day 28 score minus Baseline score.

Time frame:
Baseline and Day 28
Reported as:
Least squares mean · Scores on a scale (MADRS10)
Change From Baseline to Day 28 in MADRS Total Score
Scores on a scale (MADRS10)REL-1017Placebo
Change From Baseline to Day 28 in MADRS Total Score-14.81 ± 1.00-13.9 ± 1.01
SecondaryChange From Baseline to Day 7 in MADRS Total Score

Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score. The MADRS is a clinician-rated scale that assesses the severity of depressive symptoms. The total score is calculated as the sum of 10 items, each scored from 0 to 6, resulting in a total score range of 0 to 60. Lower scores indicate less severe depressive symptoms and a better outcome, whereas higher scores indicate more severe depressive symptoms and a worse outcome. The outcome measure reports the change in MADRS total score from Baseline to Day 7. Change was calculated as Day 7 score minus Baseline score.

Time frame:
Day 7
Reported as:
Least squares mean · Scores on a scale (MADRS10)
Change From Baseline to Day 7 in MADRS Total Score
Scores on a scale (MADRS10)REL-1017Placebo
Change From Baseline to Day 7 in MADRS Total Score-9.66 ± 0.77-7.02 ± 0.78
SecondaryChange From Baseline to Day 28 in Clinical Global Impression-Severity (CGI-S) Score

Clinical Global Impression-Severity (CGI-S) is a clinician-rated assessment of illness severity. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). Lower scores indicate less severe illness and a better outcome, whereas higher scores indicate more severe illness and a worse outcome. The outcome measure reports the change in CGI-S score from Baseline to Day 28. Change was calculated as Day 28 score minus Baseline score

Time frame:
Day 28
Reported as:
Least squares mean · Scores on a scale (CGI-S)
Change From Baseline to Day 28 in Clinical Global Impression-Severity (CGI-S) Score
Scores on a scale (CGI-S)REL-1017Placebo
CGI-S Day 28-1.36 ± 0.11-1.24 ± 0.11
CGI-S Day 7-0.74 ± 0.08-0.48 ± 0.08
SecondaryMADRS10 Remission Rate at Day 28

Remission was defined as a Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score ≤10 at Day 28. The MADRS total score ranges from 0 to 60, with lower scores indicating less severe depressive symptoms and a better outcome.

Time frame:
Day 28
Reported as:
Count of participants · Participants
MADRS10 Remission Rate at Day 28
ParticipantsREL-1017Placebo
MADRS10 Remission Rate at Day 283423
SecondaryMADRS10 Response Rate at Day 28

Response was defined as a ≥50% reduction from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score. The MADRS total score ranges from 0 to 60, with lower scores indicating less severe depressive symptoms and a better outcome.

Time frame:
Day 28
Reported as:
Count of participants · Participants
MADRS10 Response Rate at Day 28
ParticipantsREL-1017Placebo
MADRS10 Response Rate Day 285145
MADRS10 Response Rate Day 72513

Adverse events

Collected over TEAE that starts or worsens at any time after initiation of study drug collected up to 14 days post treatment (Day 42).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
REL-10170/119 (0%)0/119 (0%)47/119 (39.5%)
Placebo0/117 (0%)0/117 (0%)57/117 (48.7%)
Most frequent other events
Showing 10 of 91
Most frequent other events
EventREL-1017Placebo
HeadacheNervous system disorders5/1199/117
NauseaGastrointestinal disorders3/1195/117
InsomniaPsychiatric disorders2/1195/117
PalpitationsCardiac disorders1/1195/117
DizzinessNervous system disorders3/1194/117
DiarrhoeaGastrointestinal disorders3/1194/117
COVID-19Infections and infestations2/1194/117
SonnolenceNervous system disorders4/1191/117
Upper respiratory tract infectionInfections and infestations4/1191/117
FatigueGeneral disorders4/1193/117

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)REL-1017PlaceboTotal
<=18 years000
Between 18 and 65 years119117236
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)REL-1017PlaceboTotal
Female8984173
Male303363
Race (NIH/OMB)
Race (NIH/OMB)(Participants)REL-1017PlaceboTotal
American Indian or Alaska Native011
Asian347
Native Hawaiian or Other Pacific Islander000
Black or African American151227
White9797194
More than one race437
Unknown or Not Reported000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)REL-1017PlaceboTotal
Hispanic or Latino243357
Not Hispanic or Latino9380173
Unknown or Not Reported246
08

Study locations

70 sites
  • Relmada Site
    Homewood, Alabama 35209, United States
  • Relmada Site
    Chandler, Arizona 85226, United States
  • Relmada Site
    Chandler, Arizona 85286, United States
  • Relmada Site
    Phoenix, Arizona 85016, United States
  • Relmada Site
    Tucson, Arizona 85704, United States
  • Relmada Site
    Bryant, Arkansas 72022, United States
  • Relmada Site
    Anaheim, California 92805, United States
  • Relmada Site
    Bellflower, California 90706, United States
  • Relmada Site
    Encino, California 91316, United States
  • Relmada Site
    Lafayette, California 94549, United States
  • Relmada Site
    Los Angeles, California 90015, United States
  • Relmada Site
    Newport Beach, California 92660, United States
  • Relmada Site
    Orange, California 92868, United States
  • Relmada Site
    Redlands, California 92374, United States
  • Relmada Site
    Santa Ana, California 92705, United States
  • Relmada Site
    Stanford, California 94305, United States
  • Relmada Site
    Temecula, California 92591, United States
  • Relmada Site
    Upland, California 91786, United States
  • Relmada Site
    Denver, Colorado 80209, United States
  • Relmada Site
    Brandon, Florida 33511, United States
  • Relmada Site
    Hialeah, Florida 33015, United States
  • Relmada Site
    Jacksonville, Florida 32256, United States
  • Relmada Site
    Maitland, Florida 32751, United States
  • Relmada Site
    Miami, Florida 33122, United States
  • Relmada Site
    Miami, Florida 33125, United States
  • Relmada Site
    Miami, Florida 33133, United States
  • Relmada Site
    Miami, Florida 33136, United States
  • Relmada Site
    Miami, Florida 33174, United States
  • Relmada Site
    Miami Springs, Florida 33166, United States
  • Relmada Site
    Okeechobee, Florida 34972, United States
  • Relmada Site
    Tampa, Florida 33607, United States
  • Relmada Site
    West Palm Beach, Florida 33407, United States
  • Relmada Site
    Savannah, Georgia 31406, United States
  • Relmada Site
    Boise, Idaho 83704, United States
  • Relmada Site
    Chicago, Illinois 60611, United States
  • Relmada Site
    Chicago, Illinois 60634, United States
  • Relmada Site
    Elgin, Illinois 60123, United States
  • Relmada Site
    Overland Park, Kansas 66210, United States
  • Relmada Site
    Marrero, Louisiana 70072, United States
  • Relmada Site
    Baltimore, Maryland 21208, United States
  • Relmada Site
    Bel Air, Maryland 21015, United States
  • Relmada Site
    Gaithersburg, Maryland 20877, United States
  • Relmada Site
    Boston, Massachusetts 02131, United States
  • Relmada Site
    Bloomfield Hills, Michigan 48302, United States
  • Relmada Site
    Mankato, Minnesota 56001, United States
  • Relmada Site
    Weldon Spring, Missouri 63304, United States
  • Relmada Site
    Las Vegas, Nevada 89121, United States
  • Relmada Site
    Toms River, New Jersey 08755, United States
  • Relmada Site
    Cedarhurst, New York 11516, United States
  • Relmada Site
    Monroe, North Carolina 28112, United States
  • Relmada Site
    Beachwood, Ohio 44122, United States
  • Relmada Site
    Cincinnati, Ohio 45215, United States
  • Relmada Site
    Cincinnati, Ohio 45219, United States
  • Relmada Site
    Westlake, Ohio 44145, United States
  • Relmada Site
    Philadelphia, Pennsylvania 19104, United States
  • Relmada Site
    State College, Pennsylvania 16801, United States
  • Relmada Site
    Memphis, Tennessee 38119, United States
  • Relmada Site
    Austin, Texas 78737, United States
  • Relmada Site
    Austin, Texas 78759, United States
  • Relmada Site
    Beaumont, Texas 77702, United States
  • Relmada Site
    Bellaire, Texas 77401, United States
  • Relmada Site
    Dallas, Texas 75243, United States
  • Relmada Site
    Friendswood, Texas 77546, United States
  • Relmada Site
    Houston, Texas 77081, United States
  • Relmada Site
    Sherman, Texas 75092, United States
  • Relmada Site
    Wichita Falls, Texas 76309, United States
  • Relmada Site
    Draper, Utah 84020, United States
  • Relmada Site
    Rutland, Vermont 05701, United States
  • Relmada Site
    Portsmouth, Virginia 23703, United States
  • Relmada Site
    Everett, Washington 98201, United States
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Dec 2024, 45 months.

Results were first posted in Jul 2026, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2021
First posted
Apr 22, 2021
StartActual
Mar 30, 2021
Primary completionActual
Dec 31, 2024
CompletionActual
Jan 14, 2025
Results first posted
Jul 10, 2026
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04855747
Lead sponsor
Levomecor Inc.
Responsible party
Sponsor
First posted
Apr 22, 2021
Start date
Mar 30, 2021
Primary completion
Dec 31, 2024
Completion
Jan 14, 2025
Results posted
Jul 10, 2026
Last update
Jul 10, 2026

Study contacts

Paul Greene, PhD
study director · Relmada Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: D-methadone

Start the discussion